{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'respective anatomic areas may be used if performed consistently throughout the study for', 'each individual subject and only under the circumstances described in Appendix G. Scans', 'of the chest and abdomen must be obtained; scans of the neck and pelvis must also be', 'obtained if there is documented or suspected involvement in these regions. Screening', 'radiographic assessment must include brain MRI/CT. Diagnostic/baseline pre-first-line', 'scans through screening scans will be reviewed by the investigator to determine disease', 'response status per RECIST v1.1 for eligibility and stratification. On study disease', 'response will be determined by the Investigator at each assessment according to', 'RECIST v1.1 (Appendix G, Response Evaluation Criteria for Solid Tumors', '(RECIST) V 1.1)12 and independently reviewed by Central Radiographic Assessment', 'Committee (described below). Disease/Response Assessment may be performed within', '7 days prior to the Day 1 visit.', 'Effusion (pleural, pericardial, etc.) assessments will be performed by a radiologist at each', 'on-study radiographic assessment and any new findings communicated to the Investigator', 'prior to the next dose of blinded investigational product. Effusions should contribute to', 'disease status assessment per RECIST V 1.1 only if confirmed malignant by cytology or', 'otherwise clearly disease-related; if disease progression is suspected solely based on the', 'appearance of new or increase of existing effusions, confirmation of malignant nature of', 'such effusions is strongly recommended due to known adverse event profile of', 'rovalpituzumab tesirine. If collected, effusion fluid must be tested for cytology if disease', 'progression due to appearance/worsening of effusion is suspected.', 'Isolated CNS-only progression will not require removal of the subject from therapy.', 'Refer to Section 5.2.3.2.1, Allowed Concomitant Therapy for details associated with CNS', 'only progression.', 'The EOT assessment may be omitted if the previous assessment was performed within the', 'preceding 6 weeks.', 'Scheduled tumor assessments should not be affected by delays in therapy and/or drug', 'holidays. Subjects will continue to be monitored by the same diagnostic method', '50']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'throughout the study every 6 weeks after randomization, unless evidence of tumor', 'progression warrants otherwise. In some cases, mandatory dose delays due to toxicity', 'will lead to a gap between tumor assessment and dosing. In cases where this gap exceeds', '1 week, the TAMD should be contacted for guidance.', 'Subjects who discontinue treatment for reasons other than radiographic disease', 'progression will continue to be followed every 6 weeks from randomization to determine', 'the extent of tumor burden, until disease progression occurs.', 'MRI/CT of the Brain', 'MRI of the brain will be performed at protocol-specified time points as outlined in', 'Appendix C, Study Activities. Brain MRI may be substituted by CT with intravenous', 'contrast at the discretion of the Investigator. MRI/CT of the brain is required at screening', 'and when clinically indicated (e.g., if CNS progression is suspected) thereafter.', 'Central Radiographic Assessment Committee (CRAC)', 'In addition to being reviewed by the investigator and/or site staff, radiological scans will', 'be assessed by a Central Radiographic Assessment Committee (CRAC), as outlined in the', 'Appendix C, Study Activities. Sites will collect the appropriate scans and ship by courier', \"or submit electronically to the central facility at each subject's disease assessment. If, in\", 'addition to protocol-specified disease assessment modalities other modalities were used to', 'assess disease (e.g., FDG-PET, X-ray), imaging should also be transferred to the central', 'facility.', 'The EOT assessment may be omitted if the previous assessment was performed within the', 'preceding 6 weeks.', 'Subject treatment management will be based on review by the local investigator and/or', 'site staff. The investigator should treat according to clinical judgment and the CRAC will', 'make the definitive decision on tumor response or progression in regards to the PFS', 'endpoint.', '51']\n\n###\n\n", "completion": "END"}